Glaucoma, Intraocular Pressure
Conditions
Keywords
Glaucoma, Anecortave Acetate, Intraocular pressure, Advanced glaucoma cases with uncontrolled IOP
Brief summary
Introduction: Ocular administration of glucocorticoids is a common and effective treatment for several ocular diseases. However it is often complicated with the elevation of intraocular pressure (IOP). Anecortave acetate (AA) is an analog of cortisol acetate and lacks the typical anti-inflammatory and immunosuppressive properties of glucocorticoids. The effect of its anterior juxtascleral depot (AJD) injection has been evaluated in cases of glaucoma caused by intravitreal triamcinolone acetonide, presenting impressive results. The purpose of this study is to evaluate the efficacy and safety of the AA injection as a possible antiglaucoma treatment alternative. Methods: A prospective clinical study will be carried out including 30 glaucoma patients (30 eyes). After inclusion each patient will receive a single AJD injection of 30 mg of AA in the selected eye. Main outcome measure include: intraocular pressure at 1st day, 7th day, 1st, 2nd and 3rd months.
Interventions
DRUGAnterior Juxtascleral Depot of Anecortave Acetate
Sponsors
Alcon Research
Federal University of São Paulo
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Advanced glaucoma cases with surgery or cyclophotocoagulation indication (IOP over 25 mmHg) * Patients should be under maximum tolerated medication * Low best corrected visual acuity (worse than 20/100)
Exclusion criteria
* Under 18 or over 80
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure | Procedure |
Secondary
| Measure | Time frame |
|---|---|
| Visual Acuity; side effects (biomicroscopy exam) | Post treatment |
Countries
Brazil
Outcome results
None listed